Arcus Biosciences prices a $250 million public stock offering at $17.50 per share, according to multiple outlets. The announcement and pricing come after market reaction to the company’s offering plan, with some reports highlighting subsequent share-price moves.
Outlets frame the story around both the financing terms and the market response. Seeking Alpha emphasizes a sharper negative reaction, describing a sizable slide linked to the offering and also referencing kidney-cancer data. Investing.com focuses more directly on the offering itself—first noting the stock fall tied to the announcement, and then reporting the final pricing at the same stated $17.50.
Across coverage, the central agreed points are the offering size, the per-share price, and the fact that the stock declines around the news, though the depth of additional context (such as clinical data) differs by outlet.